Publicly-traded company BioPharmX Corporation (NYSE:BPMX) had a closing price of $0.12 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $1.05, this means that the stock is underpriced by 88.571%. In the past 52 weeks the company’s stock price has moved within the range of $0.10 to $0.90.

This particular stock’s 5-day moving average is 0.11, its 20-day moving average is 0.11 and its 100-day moving average is 0.23. BioPharmX Corporation (BPMX) currently has 127510 shares outstanding, which means that its market capitalization is $15.40M.

The Details: BioPharmX Corporation (BPMX) Financial Health

We can also look at Return on Assets, which is a percentage that tells us how good a public company is at using its current assets to generate a profit. Higher percentages mean that the company is better at using its assets. At the moment, BioPharmX Corporation Return on Assets is -326.90% .

What Does Wall Street Say about Company?

When selecting stocks to purchase, many investors want to know what Wall Street analysts are thinking before they pull the trigger. They often look for the average analyst rating. At the moment, the average analyst rating for BPMX is Buy. Out of 2 total analysts who were surveyed, 0 rated it hold, and 2 rated it a Strong Buy.

Three months ago, on the other hand, the average analyst rating for BioPharmX Corporation (BPMX) was a Buy – from a survey of 3 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, and 3 rated it a Strong Buy.

Understanding Profitability at BioPharmX Corporation (BPMX)

A good method of evaluating a public company’s profitability is by taking a look at its Earnings per Share (EPS) performance. In the most recent financial results released by BioPharmX Corporation, for the quarter ending on 2017-10-31, the company posted EPS of -0.05. The average estimate of Wall Street analysts had projected -0.05.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.04, compared to -0.09 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 2 analysts is 10000 – compared to $15000 posted in the year-ago period.